|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
139,229 |
182,993 |
316,353 |
638,922 |
Total Sell Value |
$12,316,080 |
$16,513,389 |
$28,948,007 |
$60,375,372 |
Total People Sold |
5 |
5 |
6 |
8 |
Total Sell Transactions |
11 |
15 |
24 |
57 |
End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Baffi Robert |
EVP, Technical Operations |
|
2014-10-29 |
4 |
S |
$81.10 |
$3,686,955 |
D/D |
(45,462) |
99,200 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2014-10-29 |
4 |
OE |
$17.33 |
$1,533,721 |
D/D |
45,462 |
144,662 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-10-24 |
4 |
AS |
$80.00 |
$160,000 |
I/I |
(2,000) |
46,195 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-10-24 |
4 |
OE |
$12.99 |
$25,980 |
I/I |
2,000 |
48,195 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-10-21 |
4 |
AS |
$75.00 |
$150,000 |
I/I |
(2,000) |
46,195 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-10-21 |
4 |
OE |
$12.99 |
$25,980 |
I/I |
2,000 |
48,195 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2014-09-19 |
4 |
AS |
$69.75 |
$1,223,136 |
D/D |
(17,536) |
64,426 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2014-09-19 |
4 |
OE |
$21.51 |
$377,199 |
D/D |
17,536 |
81,962 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2014-09-03 |
4 |
S |
$69.70 |
$1,256 |
D/D |
(18) |
68,733 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2014-09-02 |
4 |
S |
$69.83 |
$1,117,314 |
D/D |
(16,000) |
68,676 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2014-09-02 |
4 |
OE |
$39.06 |
$624,960 |
D/D |
16,000 |
84,676 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-08-20 |
4 |
AS |
$70.00 |
$350,000 |
I/I |
(5,000) |
46,195 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-08-20 |
4 |
OE |
$12.99 |
$64,950 |
I/I |
5,000 |
51,195 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2014-08-06 |
4 |
A |
$62.17 |
$870 |
D/D |
14 |
68,751 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2014-08-05 |
4 |
AS |
$65.00 |
$650,000 |
D/D |
(10,000) |
76,550 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2014-08-05 |
4 |
OE |
$21.51 |
$215,100 |
D/D |
10,000 |
86,550 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2014-08-01 |
4 |
S |
$61.76 |
$137,652 |
D/D |
(2,229) |
68,676 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-07-31 |
5 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
226,157 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2014-07-02 |
4 |
S |
$64.00 |
$142,656 |
D/D |
(2,229) |
70,905 |
|
- |
|
Grey Michael G |
Director |
|
2014-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,100 |
25,150 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2014-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
8,800 |
|
- |
|
Heron Elaine J |
Director |
|
2014-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,100 |
19,525 |
|
- |
|
Lewis Alan |
Director |
|
2014-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,100 |
21,400 |
|
- |
|
Slamon Dennis |
Director |
|
2014-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
525 |
5,225 |
|
- |
|
Young William D |
Director |
|
2014-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,100 |
10,775 |
|
- |
|
1355 Records found
|
|
Page 4 of 55 |
|
|